ARQT Stock Price, Arcutis Biotherapeutics Quote, Chart

Market Summary

USD8.64-0.81

Delayedas of 19 Apr 2024, 02:03 pm

-8.57%

ARQT Stock Price

View Fullscreen

ARQT RSI Chart

ARQT Valuation

Market Cap

914.9M

Price/Earnings (Trailing)

-3.49

Price/Sales (Trailing)

15.35

Price/Free Cashflow

-3.7

ARQT Price/Sales (Trailing)

ARQT Profitability

Operating Margin

94.59%

Return on Equity

-295.65%

Return on Assets

-76.79%

Free Cashflow Yield

-27.05%

ARQT Fundamentals

ARQT Revenue

Revenue (TTM)

59.6M

Rev. Growth (Yr)

671.59%

Rev. Growth (Qtr)

-64.51%

ARQT Earnings

Earnings (TTM)

-262.1M

Earnings Growth (Yr)

7.96%

Earnings Growth (Qtr)

-48.07%

Breaking Down ARQT Revenue

52 Week Range

9.44

(Low)(High)

Last 7 days

-20.4%

Last 30 days

-4.2%

Last 90 days

190.8%

Trailing 12 Months

-30.5%

How does ARQT drawdown profile look like?

ARQT Financial Health

Current Ratio

7.08

Debt/Equity

2.28

Debt/Cashflow

-1.22

ARQT Investor Care

Shares Dilution (1Y)

58.50%

Diluted EPS (TTM)

-3.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	17.7M	31.6M	45.6M	59.6M
2022	0	0	0	3.7M
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arcutis Biotherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	topper david joseph	acquired	-	-	110,000	chief financial officer
Mar 04, 2024	heron patrick j	bought	199,994	9.5	21,052	-
Mar 04, 2024	moore matthew richard	sold	-38,568	11.1212	-3,468	svp and chief business officer
Mar 04, 2024	watanabe todd franklin	sold	-165,739	11.1212	-14,903	see remarks
Mar 04, 2024	matsuda masaru	sold	-41,815	11.1212	-3,760	see remark
Mar 04, 2024	burnett patrick	sold	-53,181	11.1212	-4,782	see remarks
Feb 28, 2024	watanabe todd franklin	sold	-26,129	10.6	-2,465	see remarks
Feb 13, 2024	watanabe todd franklin	acquired	-	-	264,882	see remarks
Feb 13, 2024	smither john w	acquired	-	-	11,365	chief financial officer
Feb 13, 2024	burnett patrick	acquired	-	-	189,050	see remarks

Which funds bought or sold ARQT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	14.37	347,180	485,560	0.03%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	sold off	-100	-64,600	-	-%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	614	614	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	reduced	-23.67	842,862	1,470,970	-%
Apr 05, 2024	GAMMA Investing LLC	added	124	7,651	10,386	-%
Apr 05, 2024	CWM, LLC	new	-	1,000	1,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	6.00	-16,946	30,759	-%
Mar 11, 2024	VANGUARD GROUP INC	added	70.05	525,803	15,815,700	-%
Mar 04, 2024	VIMA LLC	new	-	9,690	9,690	0.02%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	340	2,966,910	4,735,190	-%

Are Funds Buying or Selling ARQT?

Are funds buying ARQT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARQT

No. of Funds

Unveiling Arcutis Biotherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	jennison associates llc	10.8%	12,128,533	SC 13G/A
Mar 06, 2024	frazier life sciences viii, l.p.	7.8%	8,785,284	SC 13D/A
Feb 14, 2024	prudential financial inc	10.47%	0	SC 13G/A
Feb 13, 2024	polar capital holdings plc	6.67%	6,297,688	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	9.99%	9,534,837	SC 13G/A
Feb 13, 2024	vanguard group inc	5.19%	4,896,513	SC 13G
Feb 12, 2024	morgan stanley	6.5%	6,093,497	SC 13G
Feb 12, 2024	rubric capital management lp	7.04%	6,644,530	SC 13G
Feb 08, 2024	jennison associates llc	9.6%	9,066,082	SC 13G
Jan 31, 2024	point72 asset management, l.p.	5.1%	4,836,116	SC 13G

Recent SEC filings of Arcutis Biotherapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	3	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 10, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	SC 13D/A	13D - Major Acquisition
Mar 06, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Arcutis Biotherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.01	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.44	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

Arcutis Biotherapeutics Inc News

Latest updates

Arcutis Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4
Revenue	-64.5%	14.00	38.00	5.00	3.00	2.00	1.00	-
Cost Of Revenue	-100.0%	-	1.00	1.00	1.00	0.00	0.00	-
Operating Expenses	-100.0%	-	75.00	72.00	79.00	71.00	105	71.00
S&GA Expenses	2.3%	49.00	48.00	46.00	43.00	37.00	35.00	19.00
R&D Expenses	-9.4%	24.00	26.00	25.00	35.00	54.00	30.00	53.00
Interest Expenses	2.7%	8.00	8.00	7.00	7.00	7.00	5.00	-
Income Taxes	-99.6%	0.00	3.00	-	-	-	-	-
Net Income	-48.1%	-66.28	-44.76	-70.99	-80.10	-72.02	-107	-71.33
Net Income Margin	25.1%	-4.40*	-5.87*	-10.45*	-18.52*	-84.50*	-	-
Free Cashflow	-27.7%	-56.25	-44.05	-66.76	-80.43	-71.19	-67.70	-51.97

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	16.5%	341	293	321	379	449	509	300	364	408	387	433	471	298	198	232	254	107
Current Assets	17.4%	330	282	309	368	437	497	295	359	403	382	428	466	293	194	228	254	106
Cash Equivalents	-16.9%	89.00	107	105	81.00	55.00	83.00	63.00	71.00	98.00	53.00	91.00	290	67.00	46.00	172	191	63.00
Inventory	-5.6%	13.00	14.00	10.00	9.00	8.00	4.00	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-11.3%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00
Liabilities	2.6%	253	246	240	240	240	238	105	110	110	24.00	18.00	20.00	28.00	25.00	23.00	13.00	6.00
Current Liabilities	11.4%	47.00	42.00	37.00	37.00	38.00	37.00	27.00	33.00	33.00	19.00	13.00	15.00	23.00	21.00	19.00	12.00	5.00
Long Term Debt	0.5%	202	201	200	199	198	197	73.00	73.00	72.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.5%	202	201	200	199	198	197	73.00	73.00	72.00	-	-	-	-	-	-	-	-
Shareholder's Equity	89.8%	89.00	47.00	81.00	140	210	271	195	254	298	363	414	451	271	173	209	242	-
Retained Earnings	-7.2%	-981	-915	-870	-799	-719	-647	-540	-472	-408	-336	-280	-238	-202	-167	-129	-94.28	-66.30
Additional Paid-In Capital	11.2%	1,071	963	952	940	930	920	737	727	706	700	695	689	473	341	339	336	1.00
Shares Outstanding	56.5%	97.00	62.00	62.00	61.00	61.00	53.00	51.00	51.00	49.00	50.00	50.00	47.00	-	-	-	-	-
Float	-	-	-	487	-	-	-	878	-	-	-	1,082	-	-	-	620	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-27.9%	-56,244	-43,984	-66,485	-80,344	-71,065	-67,695	-61,980	-56,975	-51,709	-40,884	-35,831	-46,203	-32,571	-33,691	-25,761	-21,010	-16,797	-10,722	-8,243	-7,074	-
Share Based Compensation	-12.4%	8,757	9,999	10,578	9,479	9,264	8,789	8,096	6,533	5,686	5,363	4,340	8,503	2,643	2,261	2,049	990	455	154	139	76.00	-
Cashflow From Investing	-236.5%	-62,186	45,549	89,118	107,751	42,201	-197,262	52,565	15,297	23,499	3,471	-164,919	61,996	-75,892	-91,711	6,105	-20,326	-35,999	21,096	-2,152	-9,270	-
Cashflow From Financing	11352.0%	99,289	867	1,067	100	962	284,989	1,131	14,716	72,881	63.00	1,188	207,815	129,380	-437	309	168,893	92,955	-20.00	168	-	-

ARQT Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 59,606,000	$ 3,686,000	$ 0
Operating expenses:
Cost of sales	4,987,000	754,000	0
Research and development	110,575,000	182,435,000	145,558,000
Selling, general and administrative	185,145,000	122,124,000	60,971,000
Total operating expenses	300,707,000	305,313,000	206,529,000
Loss from operations	(241,101,000)	(301,627,000)	(206,529,000)
Other income (expense):
Other income, net	11,786,000	5,821,000	173,000
Interest expense	(29,712,000)	(15,652,000)	0
Loss before income taxes	(259,027,000)	(311,458,000)	(206,356,000)
Provision for income taxes	3,113,000	0	0
Net loss	(262,140,000)	(311,458,000)	(206,356,000)
Other comprehensive income (loss):
Unrealized loss on marketable securities	1,186,000	(831,000)	(253,000)
Foreign currency translation adjustment	(96,000)	0	0
Total other comprehensive income (loss)	1,090,000	(831,000)	(253,000)
Comprehensive loss	$ (261,050,000)	$ (312,289,000)	$ (206,609,000)
Per share information:
Net loss per share, basic (in USD per share)	$ (3.78)	$ (5.66)	$ (4.18)
Net loss per share, diluted (in USD per share)	$ (3.78)	$ (5.66)	$ (4.18)
Weighted-average shares used in computing net loss per share, basic (in shares)	69,305,487	55,032,265	49,405,575
Weighted-average shares used in computing net loss per share, diluted (in shares)	69,305,487	55,032,265	49,405,575
Product revenue, net
Revenues:
Total revenues	$ 29,186,000	$ 3,686,000	$ 0
Other revenue
Revenues:
Total revenues	$ 30,420,000	$ 0	$ 0

ARQT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 88,398	$ 53,641
Restricted cash	925	1,234
Marketable securities	183,463	355,948
Trade receivables, net	25,807	8,458
Inventory	13,134	7,514
Prepaid expenses and other current assets	18,704	10,611
Total current assets	330,431	437,406
Property and equipment, net	1,539	1,881
Intangible assets, net	6,438	7,188
Operating lease right-of-use asset	2,361	2,721
Other assets	596	78
Total assets	341,365	449,274
Current liabilities:
Accounts payable	11,992	8,827
Accrued liabilities	33,941	28,323
Operating lease liability	735	657
Total current liabilities	46,668	37,807
Operating lease liability, noncurrent	3,382	4,117
Long-term debt, net	201,799	197,769
Other long-term liabilities	849	0
Total liabilities	252,698	239,693
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized; 96,787,343 and 61,052,250 shares issued at December 31, 2023 and 2022, respectively; 96,787,343 and 61,037,403 shares outstanding at December 31, 2023 and 2022, respectively	9	6
Additional paid-in capital	1,070,558	930,425
Accumulated other comprehensive income (loss)	4	(1,086)
Accumulated deficit	(981,904)	(719,764)
Total stockholders’ equity	88,667	209,581
Total liabilities and stockholders’ equity	$ 341,365	$ 449,274

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

CEO	Mr. Todd Franklin Watanabe M.A.
WEBSITE	arcutis.com
INDUSTRY	Biotechnology
EMPLOYEES	268

Arcutis Biotherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Arcutis Biotherapeutics Inc? What does ARQT stand for in stocks?

ARQT is the stock ticker symbol of Arcutis Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcutis Biotherapeutics Inc (ARQT)?

As of Thu Apr 18 2024, market cap of Arcutis Biotherapeutics Inc is 914.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARQT stock?

You can check ARQT's fair value in chart for subscribers.

What is the fair value of ARQT stock?

You can check ARQT's fair value in chart for subscribers. The fair value of Arcutis Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcutis Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARQT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcutis Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ARQT is over valued or under valued. Whether Arcutis Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Arcutis Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARQT.

What is Arcutis Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, ARQT's PE ratio (Price to Earnings) is -3.49 and Price to Sales (PS) ratio is 15.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARQT PE ratio will change depending on the future growth rate expectations of investors.